期刊文献+

过氧化物酶体增殖物激活受体在寻常性银屑病患者表皮中的表达 被引量:3

Expression of peroxisome proliferator-activated receptors in the epidermis of skin from patients with psoriasis vulgaris
原文传递
导出
摘要 目的研究过氧化物酶体增殖物激活受体(PPAR)在寻常性银屑病患者表皮角质形成细胞中的表达和意义。方法采用免疫组化方法检测PPARPPARα、β/δ、γ在5例正常人表皮、17例寻常性银屑病患者皮损及非皮损表皮中的表达,并用图像分析方法进行半定量分析。结果PPARα、β/δ、γ在正常人表皮角质形成细胞中均有不同程度的细胞核表达;在银屑病皮损表皮中的表达强度均较非皮损处下降(P〈0.01)。在银屑病非皮损表皮中,PPARβ/δ、γ的表达强度均较正常人表皮明显升高(P〈0.01)。结论PPARα表达下调可能参与了银屑病表皮角质形成细胞过度增生和分化不全的病理过程,而PPARβ/δ、γ在维持表皮细胞正常增生分化稳态中可能发挥协同作用。 Objective To investigate the expression of peroxisome proliferator-activated receptors (PPARs) in epidermal keratinocytes of patients with psoriasis vulgaris and its significance. Methods Immunohistochemical method was used to examine the expression of PPARα、β/δand γ in tissue specimens from the normal skin of 5 human controls, lesional and normal skin adjacent to the lesions of 17 patients with psoriasis vulgaris. A semi-quantitative analysis was carried out by image analyzer. Results Different levels of expression of the three PPAR isotypes were observed in the nuclei of epidermal keratinocytes of normal human controls. The expression intensity of PPARα、β/δ and γ was statistically higher in the epidermis of adjacent normal skin than that in psoriatic lesions (all P 〈 0.01 ) and normal control skin (all P 〈 0.01 ). Conclusions The decreased expression of PPARα may be associated with the overproliferation and parakeratosis of epidermal keratinoeytes in psoriatic lesions, and PPARβ/δ and γ may display a synergistic effect on the maintenance of homeostatic proliferation and differentiation of epidermal cells.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2011年第7期519-521,共3页 Chinese Journal of Dermatology
  • 相关文献

参考文献9

  • 1Berger J, Wagner JA. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol Ther 2002, 4(2): 163-174.
  • 2Green S. PPAR: a mediator of peroxisomc proliferator action. Mutat Res, 1995, 333(1-2): 101-109.
  • 3蔄茂强,孔祥明,张信江.过氧化体增生激活受体对皮肤的生物调节作用[J].临床皮肤科杂志,2007,36(3):184-186. 被引量:4
  • 4Komtives LG, Hanley K, Man MQ, et al. Keratinocyte differentia- tion in hyperproliferative epidermis: topical application of PPAR- alpha activators restores tissue homeostasis. J Invest Dermatol,2000, 115(3): 361-367.
  • 5Schmuth M, Haqq CM, Cairns WJ, et al. Peroxisome proliferator- activated receptor (PPAR)-beta/deha stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol, 2004, 122(4): 971-983.
  • 6Man MQ, Choi EH, Schmuth M, et al. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol, 2006, 126(2): 386-392.
  • 7Westergaard M, Henningsen J, Johansen C, et al. Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol, 2003, 121 (5) : 1104-1117.
  • 8Burdick AD, Kim DJ, Peraza MA, et al. The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal, 2006, 18( 1 ): 9-20.
  • 9Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors as new molecular targets in psoriasis. Curr Drug Targets Inflamm Allergy, 2004, 3(2): 205-211.

二级参考文献15

  • 1Braissant O,Wahli W.Differential expression of pemxisome proliferatoractivated receptor-alpha,-beta,and -gamma during rat embryonic development[J].Endocrinology,1998,139(6):2748-2754.
  • 2Aszterbaum M,Menon GK,Feingold KR,et al.Ontogeny of the epidermal barrier to water loss in the rat:correlation of function with stratum corneum structure and lipid Content[J].Pediatr Res,1992,31(4 Pt 1):308-317.
  • 3Hanley K,Komuves LG,Bass NM,et al.Fetal epidermal differentiation and barrier development In vivo is accelerated by nuclear hormone receptor activatom[J].J Invest Dermatol,1999,113(5):788-795.
  • 4Hanley K,Jiang Y,Crumrine D,et al.Activators of the nuclear horrnone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier[J].J Clin Invest,1997,100(3):705-712.
  • 5Schmuth M,Sehoonjans K,Yu Qc,et al.Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero[J].J Invest Dermatol,2002,119(6):1298-1303.
  • 6Michalik L,Desvergne B,Dreyer C,et al.PPAR expression and function during vertebrate development[J].Int J Dev Biol,2002,46(1):105-114.
  • 7Mao-Qiang M,Fowler AJ,Schmuth M,et al.Peroxisome-proliferator-activated receptor fPPAR)-gamma activation stimulates keratinocyte differentiation[J].J Invest Dermatol,2004,123(2):305-312.
  • 8Hanley K,Jiang Y,He SS,et al.Keratinoeyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha[J].J Invest Dermatol,1998,110(4):368-375.
  • 9Komuves LG,Hanley K,Man MQ,et al.Keratinocyte differentiation in hyperproliferative epidermis:topical application of PPARalpha activators restores tissue homeostasis[J].J Invest Dermatol,2000,1 15(3):361-367.
  • 10Schmuth M,Haqq CM,Cairns WJ,et al.Peroxisome proliferator-activated receptor fPPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes[J].J Invest Dermatol,2004,122(4):971-983.

共引文献3

同被引文献28

  • 1Exum ML,Rapp SR,Feldman SR,et al.Measuring severity of psoriasis:methodological issues[J].J Dermatol Treat 1996,(7):119-124.
  • 2Man MQ, Barish GD, Schmuth M, et al. Deficiency of PPARB/8 in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation [J]. J Invest Dermatol, 2008, 128(2): 370-377.
  • 3Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology[J]. Br J Dermatol, 2003, 149(2): 229-236.
  • 4Romauowska M, Reilly L, Palmer CN, et al. Activation of PPARbeta/ delta causes a psoriasis-like skin disease in vivo [Jl. PLoS One, 2010, 16, 5(3): e9701.
  • 5al Yacoub N, Romanowska M, Krauss S, et al. PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells [J]. J Invest Dermatol, 2008, 128(8): 1940-1949.
  • 6Villarrubia VG, Vidal-Asensi S, Perez-Bafiaseo V, et al. Lipid nutrition and the epidermal barrier: The connection between immune-mediated inflammatory diseases and peroxisome proliferator-activated receptors, a new therapeutic target in psoriasis and atopic dermatitis [J]. Actas Dermosifiliogr, 2010, 101(7): 585-599.
  • 7Romanowska M, al Yacoub N, Seidel H, et al. PPARdeha enhances keratinocyte proliferation in psoriasis and induces heparin- binding EGF-like growth factor[Jl. J Invest Dermatol, 2008, 128 (1): 110-124.
  • 8El Eishi N, Hegazy R, Abou Zeid O, et al. Peroxisome proliferator receptor (PPAR) 13/δ in psoriatic patients before and after two conventional therapeutic modalitics: methotrexate and PUVA[J]. Eur J Dermatol, 2011, 21(5): 691-695.
  • 9Hao CM, Redha R, Morrow J, et al. Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress[J]. J Biol Chem, 2002, 277(24): 21341-21345.
  • 10Burdick AD, Bility MT, Girroir EE, et al. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/ delta) inhibits cell growth of human N/TERT-1 keratinoeytes[J]. Cell Signal, 2007, 19 (6): 1163-1171.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部